Integrating Alcohol Use Into MASLD Care: A Practical Guide for Diabetes and Obesity Care Teams
Authors:
- 20 April 2026
- journal article
- review article
- Published by American Diabetes Association in Diabetes Care
- Vol. 49 (11) , 1917-1927
Abstract
Metabolic dysfunction–associated steatotic liver disease (MASLD) affects the majority of individuals with diabetes and severe obesity, and is one of the most common indications for liver transplantation in the U.S. Emerging evidence underscores the synergistic and detrimental impact of alcohol and metabolic disease on liver and overall health. In 2023, the nomenclature for steatotic liver disease was revised to include a new subcategory known as MetALD (metabolic dysfunction– and alcohol-associated liver disease), which acknowledges alcohol use as a cofactor in liver injury alongside metabolic risk factors. This review offers key insights into the role of alcohol use as both a direct hepatotoxin and an indirect contributor to insulin resistance, dyslipidemia, and obesity. Notably, even light-to-moderate alcohol intake may hasten MASLD progression to cirrhosis and hepatocellular carcinoma, especially in individuals with existing metabolic disease, and can worsen cardiovascular disease risk. MetALD is associated with increased all-cause, cancer-related, and liver-related mortality in comparison with MASLD, reinforcing the importance of accurate alcohol assessment in managing diabetes and obesity. Diagnosis now requires stratifying alcohol use and integrating tools such as the Alcohol Use Disorders Identification Test (AUDIT) questionnaire and phosphatidylethanol testing. The caveats and use of these tools in clinical practice are discussed. Management strategies for MASLD focus on lifestyle changes, weight loss, and medications such as glucagon-like peptide 1 receptor agonists, with emerging evidence suggesting that these agents may also reduce alcohol consumption. However, treatment data on MetALD are limited. This review offers practical guidance for health care professionals on how to integrate alcohol use into existing, recommended MASLD care pathways.Keywords
This publication has 101 references indexed in Scilit:
- PEth Cut‐Off Thresholds for Hazardous Alcohol Consumption Based on a Drinking StudyDrug Testing and Analysis, 2025
- Once-Weekly Semaglutide in Adults With Alcohol Use DisorderJAMA Psychiatry, 2025
- Reduced Alcohol Consumption and Major Adverse Cardiovascular Events Among Individuals With Previously High Alcohol ConsumptionJAMA Network Open, 2024
- Association of Habitual Alcohol Intake With Risk of Cardiovascular DiseaseJAMA Network Open, 2022
- Risks of Light and Moderate Alcohol Use in Fatty Liver Disease: Follow‐Up of Population CohortsHepatology, 2019
- Thiazolidinediones and Advanced Liver Fibrosis in Nonalcoholic SteatohepatitisJAMA Internal Medicine, 2017
- Liver fibrosis scores predict liver disease mortality in the United States populationHepatology, 2017
- Increased risk of mortality by fibrosis stage in nonalcoholic fatty liver disease: Systematic review and meta‐analysisHepatology, 2017
- Is moderate alcohol use in nonalcoholic fatty liver disease good or bad? A critical reviewHepatology, 2017
- the Incidence and Risk Factors of Hepatocellular Carcinoma in Patients With Nonalcoholic SteatohepatitisHepatology, 2010